137 related articles for article (PubMed ID: 2396995)
21. Parallel procoagulant and anticoagulant pathways for high molecular weight kininogen coagulant function.
Olson ST; Sheffer R; Shore JD
Agents Actions Suppl; 1992; 38 ( Pt 1)():241-8. PubMed ID: 1466276
[TBL] [Abstract][Full Text] [Related]
22. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets.
Jiang YP; Muller-Esterl W; Schmaier AH
J Biol Chem; 1992 Feb; 267(6):3712-7. PubMed ID: 1740422
[TBL] [Abstract][Full Text] [Related]
23. Human high molecular weight kininogen as a thiol proteinase inhibitor: presence of the entire inhibition capacity in the native form of heavy chain.
Higashiyama S; Ohkubo I; Ishiguro H; Kunimatsu M; Sawaki K; Sasaki M
Biochemistry; 1986 Apr; 25(7):1669-75. PubMed ID: 3635411
[TBL] [Abstract][Full Text] [Related]
24. Inactivation of factor XIa by plasma protease inhibitors: predominant role of alpha 1-protease inhibitor and protective effect of high molecular weight kininogen.
Scott CF; Schapira M; James HL; Cohen AB; Colman RW
J Clin Invest; 1982 Apr; 69(4):844-52. PubMed ID: 7076850
[TBL] [Abstract][Full Text] [Related]
25. A mechanism for hereditary angioedema caused by a methionine-379-to-lysine substitution in kininogens.
Dickeson SK; Kumar S; Sun MF; Litvak M; He TZ; Phillips DR; Roberts ET; Feener EP; Law RHP; Gailani D
Blood; 2024 Feb; 143(7):641-650. PubMed ID: 37992228
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory and antiadhesive properties of human kininogens.
Colman RW
Immunopharmacology; 1996 May; 32(1-3):9-18. PubMed ID: 8796259
[TBL] [Abstract][Full Text] [Related]
27. Evidence for the presence of a kininogen-like species in a case of total deficiency of low and high molecular weight kininogens.
Veloso D
Braz J Med Biol Res; 1998 Jul; 31(7):901-10. PubMed ID: 9698753
[TBL] [Abstract][Full Text] [Related]
28. Immunovisualization of high (HK) and low (LK) molecular weight kininogens on isolated human neutrophils.
Figueroa CD; Henderson LM; Kaufmann J; De La Cadena RA; Colman RW; Müller-Esterl W; Bhoola KD
Blood; 1992 Feb; 79(3):754-9. PubMed ID: 1732013
[TBL] [Abstract][Full Text] [Related]
29. Conformational changes in low molecular weight kininogen alters its ability to bind to endothelial cells.
Hasan AA; Zhang J; Samuel M; Schmaier AH
Thromb Haemost; 1995 Oct; 74(4):1088-95. PubMed ID: 8560418
[TBL] [Abstract][Full Text] [Related]
30. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface.
DeLa Cadena RA; Colman RW
Protein Sci; 1992 Jan; 1(1):151-60. PubMed ID: 1304876
[TBL] [Abstract][Full Text] [Related]
31. Rapid direct determination of low and high molecular weight kininogen in human plasma by Particle Concentration Fluorescence Immunoassay (PCFIA).
Scott CF; Shull B; Müller-Esterl W; Colman RW
Thromb Haemost; 1997 Jan; 77(1):109-18. PubMed ID: 9031459
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of vitronectin-mediated haptotaxis and haptoinvasion of MG-63 cells by domain 5 (D5(H)) of human high-molecular-weight kininogen and identification of a minimal amino acid sequence.
Kamiyama F; Maeda T; Yamane T; Li YH; Ogukubo O; Otsuka T; Ueyama H; Takahashi S; Ohkubo I; Matsui N
Biochem Biophys Res Commun; 2001 Nov; 288(4):975-80. PubMed ID: 11689005
[TBL] [Abstract][Full Text] [Related]
33. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies.
Sugi T; Mclntyre JA
Thromb Haemost; 1996 Sep; 76(3):354-60. PubMed ID: 8883270
[TBL] [Abstract][Full Text] [Related]
34. Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation.
Sugi T; McIntyre JA
Thromb Res; 1996 Oct; 84(2):97-109. PubMed ID: 8897699
[TBL] [Abstract][Full Text] [Related]
35. Cystatins as calpain inhibitors: engineered chicken cystatin- and stefin B-kininogen domain 2 hybrids support a cystatin-like mode of interaction with the catalytic subunit of mu-calpain.
Díaz BG; Gross S; Assfalg-Machleidt I; Pfeiler D; Gollmitzer N; Gabrijelcic-Geiger D; Stubbs MT; Fritz H; Auerswald EA; Machleidt W
Biol Chem; 2001 Jan; 382(1):97-107. PubMed ID: 11258679
[TBL] [Abstract][Full Text] [Related]
36. Parallel reduction of plasma levels of high and low molecular weight kininogen in patients with cirrhosis.
Cugno M; Scott CF; Salerno F; Lorenzano E; Müller-Esterl W; Agostoni A; Colman RW
Thromb Haemost; 1999 Nov; 82(5):1428-32. PubMed ID: 10595632
[TBL] [Abstract][Full Text] [Related]
37. Kininogens: More than cysteine protease inhibitors and kinin precursors.
Lalmanach G; Naudin C; Lecaille F; Fritz H
Biochimie; 2010 Nov; 92(11):1568-79. PubMed ID: 20346387
[TBL] [Abstract][Full Text] [Related]
38. High molecular weight kininogen, the extracellular inhibitor of thiol proteases, is deficient in hamsters with muscular dystrophy.
Colman RW; Bradford HN; Warner AH
Thromb Res; 1989 Apr; 54(2):115-23. PubMed ID: 2473540
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of thrombin-induced platelet aggregation by high molecular weight kininogen.
Puri RN; Gustafson EJ; Zhou FX; Bradford H; Colman RF; Colman RW
Trans Assoc Am Physicians; 1987; 100():232-40. PubMed ID: 3455067
[TBL] [Abstract][Full Text] [Related]
40. Lack of clinically significant contact system activation during platelet concentrate filtration by leukocyte removal filters.
Scott CF; Brandwein H; Whitbread J; Colman RW
Blood; 1998 Jul; 92(2):616-22. PubMed ID: 9657763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
